In a filing, Mirum Pharmaceuticals Inc revealed its SVP, GLOBAL CONTROLLER Howe Jolanda unloaded Company’s shares for reported $27213.0 on Jul 02 ’25. In the deal valued at $48.25 per share,564 shares were sold. As a result of this transaction, Howe Jolanda now holds 2,903 shares worth roughly $0.15 million.
Then, Howe Jolanda sold 477 shares, generating $23,411 in total proceeds. Upon selling the shares at $49.08, the SVP, GLOBAL CONTROLLER now owns 2,426 shares.
Before that, JOLANDA MARIE HOWE bought 477 shares. Mirum Pharmaceuticals Inc shares valued at $23,411 were divested by the Officer at a price of $49.08 per share.
A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering MIRM and reiterated its “Buy” recommendation on December 18, 2023.
Price Performance Review of MIRM
On Tuesday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock fall -0.62% to $51.17. Over the last five days, the stock has lost -1.95%. Mirum Pharmaceuticals Inc shares have risen nearly 26.75% since the year began. Nevertheless, the stocks have risen 23.75% over the past one year. While a 52-week high of $54.78 was reached on 07/14/25, a 52-week low of $36.20 was recorded on 04/09/25.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 50.65, which if violated will result in even more drops to 50.12. On the upside, there is a resistance level at 51.97. A further resistance level may holdings at 52.76.
How much short interest is there in Mirum Pharmaceuticals Inc?
A steep rise in short interest was recorded in Mirum Pharmaceuticals Inc stocks on 2025-07-15, growing by 0.36 million shares to a total of 6.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 6.22 million shares. There was a rise of 5.51%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 13, 2023 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
